Open Innovation in Pharma & Biotech, 17th - 18th November 2016, Vienna (Austria)
Recent analysis of the current state of open innovation in Pharma & Biotech has revealed a higher success rate for open innovation than for closed-model product development. However, companies have admitted that around 80% of their R&D pipeline comes via the more closed-end of the open innovation spectrum. Adoption of open approaches is still infrequent and slower, mainly due to concerns about intellectual property rights, cultural and management...